{"id":"NCT01932970","sponsor":"Amgen","briefTitle":"Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide","officialTitle":"A Multicenter, Multiple-dose, Single-arm Study to Switch Hemodialysis Subjects With Secondary Hyperparathyroidism From Oral Cinacalcet HCl to Intravenous AMG 416","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08-12","primaryCompletion":"2014-01-14","completion":"2017-02-14","firstPosted":"2013-08-30","resultsPosted":"2017-04-04","lastUpdate":"2018-10-17"},"enrollment":158,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hyperparathyroidism, Secondary"],"interventions":[{"type":"DRUG","name":"Etelcalcetide","otherNames":["KAI 4169","AMG 416","Parsabivâ„¢"]}],"arms":[{"label":"Etelcalcetide","type":"EXPERIMENTAL"}],"summary":"This is a multicenter, multiple-dose, single-arm, open-label study to assess the impact on serum corrected calcium levels when switching patients from cinacalcet to etelcalcetide (AMG 416).","primaryOutcome":{"measure":"Percentage of Participants With Serum Corrected Calcium < 7.5 mg/dL During the 4-week Treatment Period","timeFrame":"4 weeks","effectByArm":[{"arm":"Etelcalcetide","deltaMin":0.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":40,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":148},"commonTop":[]}}